<DOC>
	<DOCNO>NCT00950170</DOCNO>
	<brief_summary>Study evaluate safety effectiveness ReFacto AF treatment severe hemophilia A patient yet receive treatment hemophilia . Study subject male less 6 year old take clot factor blood product study . The safety effectiveness ReFacto AF determine study test procedures do doctor 's office .</brief_summary>
	<brief_title>Study Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting</brief_title>
	<detailed_description>Regulatory Commitment</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male subject &lt; 6 year age severe hemophilia A ( FVIII : C &lt; 1 % ) base clinical record , include newborn . No prior exposure factor product blood product . Presence bleed disorder addition hemophilia A . Treatment investigational agent device within past 30 day . Any condition ( ) compromise ability collect studyrelated observation , pose contraindication study participation ( condition include , limited , inadequate medical history assure study eligibility ; expectation poor adherence study requirement ) .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ReFacto AF</keyword>
	<keyword>factor VIII</keyword>
	<keyword>inhibitor</keyword>
	<keyword>antibody</keyword>
</DOC>